FractalDx Kidney Transplant Diagnostic Portfolio
FractalDx is a portfolio of advanced diagnostic and prognostic solutions used in kidney transplant to assess the immune status of recipients in order to predict risk of adverse outcomes including sub-acute clinical rejection, early acute kidney rejection and overall graft loss.
The comprehensive range of clinical diagnostics tests will be used both pre and post-transplant in an effort to reduce the incidence rate of over 30% of kidney transplant recipients who experience graft loss and rejection in the first five years post-transplant.
The FractalDx technology is based principally on sequencing multiple genes (biomarkers) from a patient’s blood or biopsy tissue using widely available instrument platforms.
The initial products currently under development from the FractalDx portfolio include:
FractalDx ACR – A post-transplant test used to diagnose patients with sub-clinical acute clinical rejection (i.e. before clinical symptoms) in first 12 months post transplant.
Fractal Baseline Dx – A pre-transplant diagnostic used to identify transplant patients at elevated risk of early acute rejection (<6 months).
FractalDx Fibrosis – A post-transplant diagnostic used to predict the development of fibrosis and graft survival at 12 and 24 months.